Eliem Therapeutics Key Executives
This section highlights Eliem Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Eliem Therapeutics
(Showing 0 of )
Eliem Therapeutics Earnings
This section highlights Eliem Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
$5.11
Stock Price
$342.68M
Market Cap
17
Employees
Redmond, WA
Location
Financial Statements
Access annual & quarterly financial statements for Eliem Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $15.41M | $26.21M | $23.32M | $9.34M | $4.02M |
| General and Administrative Expenses | $9.89M | $18.92M | $12.35M | $2.42M | $677.00K |
| Selling and Marketing Expenses | $24.85M | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $9.89M | $18.92M | $12.35M | $2.42M | $677.00K |
| Other Expenses | $- | $1.38M | $-11.64M | $- | $914.00K |
| Operating Expenses | $37.41M | $45.13M | $35.67M | $11.77M | $4.70M |
| Cost and Expenses | $37.41M | $45.13M | $35.67M | $11.77M | $4.70M |
| Interest Income | $- | $1.20K | $450 | $- | $- |
| Interest Expense | $- | $1.59M | $- | $- | $- |
| Depreciation and Amortization | $21.47M | $45.13M | $35.67M | $11.77M | $4.70M |
| EBITDA | $-13.65M | $-43.65M | $-35.50M | $-2.87M | $-1.93M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-21.47M | $-45.13M | $-35.67M | $-20.93M | $-7.45M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-13.65M | $-109.00K | $-11.81M | $257.00K | $899.00K |
| Income Before Tax | $-35.12M | $-45.24M | $-47.48M | $-20.67M | $-6.55M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-21.47K | $109.00K | $-66.56K | $-9.16M | $-2.75M |
| Net Income | $-35.12M | $-45.35M | $-47.48M | $-11.51M | $-3.80M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.30 | $-1.72 | $-1.81 | $-0.44 | $-0.14 |
| EPS Diluted | $-1.30 | $-1.72 | $-1.81 | $-0.44 | $-0.14 |
| Weighted Average Shares Outstanding | 26.99M | 26.31M | 26.24M | 26.32M | 26.32M |
| Weighted Average Shares Outstanding Diluted | 26.99M | 26.31M | 26.24M | 26.32M | 26.32M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $1.05M | $1.09M | $3.13M | $2.88M | $3.69M | $5.72M | $4.93M | $4.26M | $8.77M | $8.26M | $6.88M | $5.99M | $5.79M | $4.66M | $4.41M | $1.95M | $1.36M | $1.62M |
| General and Administrative Expenses | $3.67M | $1.91M | $2.00M | $2.12M | $3.03M | $17.72M | $4.63M | $4.49M | $4.93M | $4.87M | $3.82M | $3.39M | $2.91M | $2.22M | $1.54M | $312.00K | $248.00K | $328.00K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.67M | $1.91M | $2.00M | $2.12M | $3.03M | $17.72M | $4.63M | $4.49M | $4.93M | $4.87M | $3.82M | $3.39M | $2.91M | $2.22M | $1.54M | $312.00K | $248.00K | $328.00K |
| Other Expenses | $1.49M | $- | $-2.26M | $- | $1.11M | $1.15M | $760.00K | $383.00K | $147.00K | $85.00K | $60.00K | $20.00K | $315.00K | $-11.72M | $- | $- | $- | $- |
| Operating Expenses | $4.71M | $3.00M | $5.12M | $5.00M | $6.71M | $23.44M | $9.55M | $8.75M | $13.70M | $13.13M | $10.70M | $9.38M | $8.71M | $6.88M | $5.95M | $2.26M | $1.61M | $1.95M |
| Cost and Expenses | $4.71M | $3.00M | $5.12M | $5.00M | $6.71M | $23.44M | $9.55M | $8.75M | $13.70M | $13.13M | $10.70M | $9.38M | $8.71M | $6.88M | $5.95M | $2.26M | $1.61M | $1.95M |
| Interest Income | $- | $1.34M | $1.35M | $1.26M | $1.11K | $409 | $- | $383.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $1.15M | $- | $- | $- | $- | $- | $1.64M | $229.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $3.00M | $3.06M | $4.78M | $5.98M | $7.65M | $9.55M | $8.75M | $13.70M | $13.13M | $10.70M | $9.38M | $8.71M | $6.88M | $5.95M | $2.26M | $1.61M | $1.95M |
| EBITDA | $-56.37M | $-3.00M | $-5.12M | $-5.00M | $-6.71M | $-23.44M | $-6.15M | $-8.75M | $-13.70M | $-13.13M | $-10.70M | $-9.38M | $-8.71M | $-6.88M | $-5.95M | $-460.00K | $-475.00K | $-404.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-4.71M | $-3.00M | $-5.12M | $-5.00M | $-6.71M | $-23.44M | $-9.55M | $-8.75M | $-13.70M | $-13.13M | $-10.70M | $-9.38M | $-8.71M | $-6.88M | $-15.11M | $-2.26M | $-1.61M | $-1.95M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-50.18M | $1.31M | $1.48M | $1.03M | $1.49M | $1.15M | $1.79M | $-934.00K | $-895.00K | $-72.00K | $158.00K | $-232.00K | $-12.00K | $-11.72M | $-8.91M | $1.00K | $-23.00K | $35.00K |
| Income Before Tax | $-54.89M | $-1.70M | $-3.64M | $-3.97M | $-5.22M | $-22.29M | $-7.76M | $-9.68M | $-14.60M | $-13.20M | $-10.54M | $-9.62M | $-8.72M | $-18.60M | $-14.86M | $-2.26M | $-1.63M | $-1.92M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $-3.00M | $-3.06K | $-4.78K | $-506.08K | $-1.15M | $-1.79M | $-7.43M | $895.00K | $72.00K | $-468.00K | $-9.13M | $-8.70M | $-6.88M | $-9.16M | $-2.26M | $-1.58M | $-1.99M |
| Net Income | $-54.89M | $-1.70M | $-3.64M | $-3.97M | $-5.22M | $-21.14M | $-5.97M | $-9.68M | $-15.49M | $-13.28M | $-10.54M | $-9.62M | $-8.72M | $-18.60M | $-14.86M | $-2.26M | $-1.63M | $-1.92M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.81 | $-0.06 | $-0.13 | $-0.15 | $-0.19 | $-0.80 | $-0.23 | $-0.37 | $-0.59 | $-0.51 | $-0.40 | $-0.62 | $-0.37 | $-1.60 | $-1.27 | $-0.19 | $-0.14 | $-0.16 |
| EPS Diluted | $-1.81 | $-0.06 | $-0.13 | $-0.15 | $-0.19 | $-0.80 | $-0.23 | $-0.37 | $-0.59 | $-0.51 | $-0.40 | $-0.62 | $-0.37 | $-1.60 | $-1.27 | $-0.19 | $-0.14 | $-0.16 |
| Weighted Average Shares Outstanding | 30.35M | 27.64M | 27.70M | 27.07M | 26.84M | 26.49M | 26.37M | 26.34M | 26.30M | 26.24M | 26.23M | 15.59M | 23.46M | 11.66M | 11.66M | 11.66M | 11.66M | 11.66M |
| Weighted Average Shares Outstanding Diluted | 30.35M | 27.64M | 27.70M | 27.07M | 26.84M | 26.49M | 26.37M | 26.34M | 26.30M | 26.24M | 26.23M | 15.59M | 23.46M | 11.66M | 11.66M | 11.66M | 11.66M | 11.66M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $93.11M | $43.59M | $46.92M | $20.49M | $21.22M |
| Short Term Investments | $13.69M | $79.98M | $89.56M | $- | $- |
| Cash and Short Term Investments | $106.80M | $123.57M | $136.48M | $20.49M | $21.22M |
| Net Receivables | $2.02M | $6.49M | $- | $- | $- |
| Inventory | $- | $-6.49M | $4.40M | $- | $- |
| Other Current Assets | $1.43M | $4.33M | $16.17M | $1.51M | $60.00K |
| Total Current Assets | $110.25M | $134.39M | $148.25M | $22.00M | $21.28M |
| Property Plant Equipment Net | $199.00K | $471.00K | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $24.92M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $15.00K | $128.00K | $70.00K | $2.63M | $112.00K |
| Total Non-Current Assets | $214.00K | $599.00K | $24.99M | $2.63M | $112.00K |
| Other Assets | $1 | $- | $- | $- | $- |
| Total Assets | $110.47M | $134.99M | $173.24M | $24.63M | $21.39M |
| Account Payables | $66.00K | $750.00K | $1.40M | $1.09M | $647.00K |
| Short Term Debt | $668.00K | $600.00K | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $-66.00K | $- | $- | $- | $- |
| Other Current Liabilities | $2.10M | $4.75M | $4.63M | $1.98M | $136.00K |
| Total Current Liabilities | $2.83M | $6.10M | $6.03M | $3.06M | $783.00K |
| Long Term Debt | $30.00K | $360.00K | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $7.00K | $-180.00K | $7.00K | $- | $- |
| Total Non-Current Liabilities | $37.00K | $180.00K | $7.00K | $- | $- |
| Other Liabilities | $1 | $- | $-0 | $- | $- |
| Total Liabilities | $2.87M | $6.28M | $6.04M | $3.06M | $783.00K |
| Preferred Stock | $- | $- | $173.24M | $46.55M | $26.17M |
| Common Stock | $3.00K | $3.00K | $3.00K | $1.00K | $1.00K |
| Retained Earnings | $-155.98M | $-120.86M | $-75.62M | $-28.14M | $-7.47M |
| Accumulated Other Comprehensive Income Loss | $-2.00K | $-358.00K | $-123.00K | $-0 | $-0 |
| Other Total Stockholders Equity | $263.58M | $249.93M | $242.94M | $3.15M | $1.91M |
| Total Stockholders Equity | $107.60M | $128.72M | $167.20M | $21.57M | $20.61M |
| Total Equity | $107.60M | $128.72M | $167.20M | $21.57M | $20.61M |
| Total Liabilities and Stockholders Equity | $110.47M | $134.99M | $173.24M | $24.63M | $21.39M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $110.47M | $134.99M | $173.24M | $24.63M | $21.39M |
| Total Investments | $13.69M | $79.98M | $114.48M | $- | $- |
| Total Debt | $349.00K | $480.00K | $- | $- | $- |
| Net Debt | $-92.76M | $-43.10M | $-46.92M | $-20.49M | $-21.22M |
Balance Sheet Charts
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $223.14M | $105.03M | $93.11M | $57.35M | $25.29M | $34.44M | $43.59M | $35.94M | $32.60M | $31.93M | $46.92M | $62.82M | $99.48M | $47.91M | $20.49M | $-21.22M |
| Short Term Investments | $- | $- | $13.69M | $50.08M | $77.34M | $74.94M | $79.98M | $86.67M | $90.35M | $92.01M | $89.56M | $83.20M | $- | $- | $- | $42.45M |
| Cash and Short Term Investments | $223.14M | $105.03M | $106.80M | $107.43M | $102.63M | $109.37M | $123.57M | $122.62M | $122.95M | $123.94M | $136.48M | $146.02M | $99.48M | $47.91M | $20.49M | $21.22M |
| Net Receivables | $- | $2.02M | $2.02M | $1.92M | $6.87M | $6.59M | $6.49M | $5.07M | $5.85M | $6.52M | $6.52M | $- | $2.54M | $2.54M | $- | $- |
| Inventory | $- | $- | $- | $2.48M | $4.12M | $-7.21M | $-6.49M | $4.93M | $3.17M | $2.22M | $-6.52M | $4.62M | $2.32M | $1.48M | $- | $- |
| Other Current Assets | $3.16M | $2.17M | $1.43M | $3.08M | $4.75M | $4.21M | $4.33M | $5.49M | $4.27M | $2.82M | $5.25M | $17.23M | $2.78M | $2.09M | $1.51M | $- |
| Total Current Assets | $226.00M | $108.27M | $110.25M | $112.43M | $114.24M | $109.37M | $134.39M | $133.17M | $133.08M | $133.28M | $148.25M | $158.63M | $104.80M | $52.54M | $22.00M | $21.22M |
| Property Plant Equipment Net | $21.00K | $111.00K | $199.00K | $286.00K | $372.00K | $662.00K | $471.00K | $585.00K | $697.00K | $807.00K | $- | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $6.96M | $11.70M | $25.91M | $24.92M | $23.62M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $-1 | $952.00K | $15.00K | $15.00K | $1.66M | $12.05M | $128.00K | $141.00K | $4.63M | $2.42M | $70.00K | $- | $2.82M | $1.15M | $2.63M | $-21.22M |
| Total Non-Current Assets | $21.00K | $1.06M | $214.00K | $301.00K | $2.03M | $12.71M | $599.00K | $7.69M | $17.03M | $29.14M | $24.99M | $23.62M | $2.82M | $1.15M | $2.63M | $-21.22M |
| Other Assets | $1 | $- | $1 | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $226.02M | $109.33M | $110.47M | $112.73M | $116.27M | $122.08M | $134.99M | $140.86M | $150.10M | $162.42M | $173.24M | $182.25M | $107.63M | $53.69M | $24.63M | $- |
| Account Payables | $509.00K | $85.00K | $66.00K | $736.00K | $878.00K | $864.00K | $750.00K | $1.49M | $1.06M | $847.00K | $1.40M | $2.58M | $1.96M | $2.00M | $1.09M | $- |
| Short Term Debt | $200.00K | $225.00K | $668.00K | $802.00K | $970.00K | $928.00K | $300.00K | $704.00K | $878.00K | $918.00K | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $-509.00K | $-85.00K | $-66.00K | $- | $- | $- | $- | $-352.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $3.03M | $2.64M | $2.10M | $1.36M | $1.77M | $3.12M | $5.05M | $4.08M | $5.67M | $5.13M | $4.63M | $3.01M | $3.76M | $2.07M | $1.98M | $- |
| Total Current Liabilities | $3.74M | $2.95M | $2.83M | $2.90M | $3.62M | $4.92M | $6.10M | $6.28M | $7.61M | $6.90M | $6.03M | $5.59M | $5.71M | $4.07M | $3.06M | $- |
| Long Term Debt | $- | $- | $30.00K | $116.00K | $200.00K | $446.00K | $180.00K | $438.00K | $512.00K | $762.00K | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $7.00K | $-24.00K | $-45.00K | $-136.00K | $- | $-219.00K | $-256.00K | $-381.00K | $7.00K | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $37.00K | $92.00K | $155.00K | $310.00K | $180.00K | $219.00K | $256.00K | $381.00K | $7.00K | $- | $- | $- | $- | $- |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $3.74M | $2.95M | $2.87M | $2.99M | $3.77M | $5.22M | $6.28M | $6.50M | $7.87M | $7.28M | $6.04M | $5.59M | $5.71M | $4.07M | $3.06M | $- |
| Preferred Stock | $- | $0 | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $182.25M | $152.76M | $92.80M | $46.55M | $26.17M |
| Common Stock | $7.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $1.00K | $1.00K | $1.00K | $- |
| Retained Earnings | $-212.56M | $-157.68M | $-155.98M | $-152.34M | $-148.37M | $-143.15M | $-120.86M | $-113.10M | $-103.42M | $-88.82M | $-75.62M | $-65.07M | $-55.46M | $-46.74M | $-28.14M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $-0 | $-2.00K | $-11.00K | $-35.00K | $-95.00K | $-358.00K | $-581.00K | $-604.00K | $-521.00K | $-123.00K | $-18.00K | $0 | $- | $-0 | $-5.56M |
| Other Total Stockholders Equity | $434.83M | $264.06M | $263.58M | $262.09M | $260.90M | $260.10M | $249.93M | $248.03M | $246.25M | $244.48M | $242.94M | $241.75M | $4.61M | $3.55M | $3.15M | $- |
| Total Stockholders Equity | $222.28M | $106.38M | $107.60M | $109.74M | $112.50M | $116.86M | $128.72M | $134.36M | $142.24M | $155.14M | $167.20M | $176.66M | $101.91M | $49.62M | $21.57M | $20.61M |
| Total Equity | $222.28M | $106.38M | $107.60M | $109.74M | $112.50M | $116.86M | $128.72M | $134.36M | $142.24M | $155.14M | $167.20M | $176.66M | $101.91M | $49.62M | $21.57M | $20.61M |
| Total Liabilities and Stockholders Equity | $226.02M | $109.33M | $110.47M | $112.73M | $116.27M | $122.08M | $134.99M | $140.86M | $150.10M | $162.42M | $173.24M | $182.25M | $107.63M | $53.69M | $24.63M | $20.61M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $226.02M | $109.33M | $110.47M | $112.73M | $116.27M | $122.08M | $134.99M | $140.86M | $150.10M | $162.42M | $173.24M | $182.25M | $107.63M | $53.69M | $24.63M | $20.61M |
| Total Investments | $- | $- | $13.69M | $50.08M | $77.34M | $74.94M | $79.98M | $93.64M | $102.05M | $117.92M | $114.48M | $106.82M | $- | $- | $- | $42.45M |
| Total Debt | $100.00K | $225.00K | $349.00K | $459.00K | $585.00K | $687.00K | $480.00K | $571.00K | $695.00K | $840.00K | $- | $- | $- | $- | $- | $- |
| Net Debt | $-223.04M | $-104.81M | $-92.76M | $-56.89M | $-24.71M | $-33.75M | $-43.10M | $-35.37M | $-31.91M | $-31.09M | $-46.92M | $-62.82M | $-99.48M | $-47.91M | $-20.49M | $21.22M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-35.12M | $-45.24M | $-47.48M | $-20.67M | $-6.55M |
| Depreciation and Amortization | $- | $- | $1.84M | $- | $- |
| Deferred Income Tax | $- | $-1.39M | $-1.84M | $- | $- |
| Stock Based Compensation | $12.81M | $6.99M | $3.74M | $707.00K | $- |
| Change in Working Capital | $3.76M | $210.00K | $-4.17M | $-2.94M | $-309.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-686.00K | $-653.00K | $150.00K | $-24.00K | $17.00K |
| Other Working Capital | $4.45M | $863.00K | $-4.32M | $-2.91M | $-326.00K |
| Other Non Cash Items | $-2.05M | $2.06M | $11.84M | $8.80M | $1.85M |
| Net Cash Provided by Operating Activities | $-20.60M | $-37.37M | $-36.07M | $-14.10M | $-5.01M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $8.28K | $- |
| Purchases of Investments | $-58.45M | $-87.96M | $-114.97M | $- | $- |
| Sales Maturities of Investments | $127.43M | $122.40M | $- | $- | $- |
| Other Investing Activities | $68.98K | $34.44K | $-114.97K | $8.07M | $- |
| Net Cash Used for Investing Activities | $68.98M | $34.44M | $-114.97M | $8.08M | $- |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $841.00K | $- | $83.14M | $4.92M | $26.24M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $841.00K | $- | $94.09M | $4.92M | $26.24M |
| Net Cash Used Provided by Financing Activities | $841.00K | $- | $177.23M | $4.92M | $26.24M |
| Effect of Forex Changes on Cash | $304.00K | $-408.00K | $245.00K | $359.00K | $-12.00K |
| Net Change in Cash | $49.53M | $-3.34M | $26.43M | $-736.00K | $21.22M |
| Cash at End of Period | $93.11M | $43.59M | $46.92M | $20.49M | $21.22M |
| Cash at Beginning of Period | $43.59M | $46.92M | $20.49M | $21.22M | $- |
| Operating Cash Flow | $-20.60M | $-37.37M | $-36.07M | $-14.10M | $-5.01M |
| Capital Expenditure | $- | $- | $- | $- | $- |
| Free Cash Flow | $-20.60M | $-37.37M | $-36.07M | $-14.10M | $-5.01M |
Cash Flow Charts
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-54.89M | $-1.70M | $-3.64M | $-3.97M | $-5.22M | $-22.29M | $-7.76M | $-9.68M | $-14.60M | $-13.20M | $-10.54M | $-9.62M | $-8.72M | $-18.60M | $-14.86M | $-2.26M | $-1.63M | $-1.92M |
| Depreciation and Amortization | $- | $-63.00K | $491.00K | $- | $- | $-491.00K | $-293.00K | $- | $293.00K | $193.00K | $370.00K | $- | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $-1.39M | $- | $- | $-193.00K | $-1.84M | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $512.00K | $465.00K | $1.20M | $656.00K | $777.00K | $10.17M | $1.90M | $1.78M | $1.77M | $1.54M | $1.15M | $1.24M | $1.05M | $297.00K | $473.00K | $49.00K | $51.00K | $134.00K |
| Change in Working Capital | $1.98M | $-640.00K | $1.42M | $7.47M | $-2.67M | $-2.46M | $-484.00K | $2.69M | $-2.40M | $406.00K | $1.22M | $-4.59M | $-727.00K | $-73.00K | $26.00K | $-341.00K | $-2.16M | $-460.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-1.18M | $20.00K | $-672.00K | $-142.00K | $14.00K | $114.00K | $-744.00K | $431.00K | $146.00K | $-486.00K | $-1.17M | $527.00K | $-129.00K | $920.00K | $-47.00K | $466.00K | $-489.00K | $46.00K |
| Other Working Capital | $1.98M | $-640.00K | $2.09M | $7.62M | $-2.69M | $-114.00K | $260.00K | $2.28M | $-2.55M | $892.00K | $2.39M | $-5.12M | $-598.00K | $-993.00K | $73.00K | $-807.00K | $-1.67M | $-506.00K |
| Other Non Cash Items | $52.24M | $518.00K | $71.00K | $-671.00K | $-850.00K | $-109.00K | $-415.00K | $112.00K | $967.00K | $478.00K | $1.76M | $4.00K | $-85.00K | $11.64M | $8.74M | $169.00K | $-27.00K | $-83.00K |
| Net Cash Provided by Operating Activities | $-667.00K | $-1.82M | $-947.00K | $3.49M | $-7.96M | $-15.18M | $-8.45M | $-4.17M | $-13.97M | $-10.78M | $-7.88M | $-12.97M | $-8.48M | $-6.74M | $-5.62M | $-2.38M | $-3.77M | $-2.33M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $-4.64M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $8.28M | $- | $- | $- |
| Purchases of Investments | $- | $- | $-1.00K | $-2.46M | $-38.53M | $-17.45M | $-6.71M | $-46.74M | $-8.93M | $-25.58M | $-8.05M | $-106.92M | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $13.75M | $36.75M | $30.50M | $36.93M | $23.25M | $20.99M | $55.25M | $24.61M | $21.55M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-5.00M | $13.75M | $36.75K | $28.04K | $-1.60K | $5.80K | $14.28K | $8.51M | $15.69K | $-4.04M | $-8.05M | $-106.92M | $- | $- | $8.08M | $- | $- | $- |
| Net Cash Used for Investing Activities | $-9.64M | $13.75M | $36.75M | $28.04M | $-1.60M | $5.80M | $14.28M | $8.51M | $15.69M | $-4.04M | $-8.05M | $-106.92M | $- | $- | $8.08M | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $128.40M | $15.00K | $288.00K | $528.00K | $24.00K | $1.00K | $- | $- | $- | $- | $38.00K | $83.14M | $59.97M | $34.08M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $-2.14M | $- | $-4.55M | $- | $-2.14M | $- | $- | $- | $- | $- |
| Other Financing Activities | $128.40M | $15.00K | $288.00K | $528.00K | $24.00K | $1.00K | $- | $- | $2.14M | $- | $38.00K | $83.14M | $62.11M | $34.08M | $4.92M | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $128.40M | $15.00K | $288.00K | $528.00K | $24.00K | $1.00K | $- | $- | $-2.14M | $- | $38.00K | $83.14M | $59.97M | $34.08M | $4.92M | $- | $- | $- |
| Effect of Forex Changes on Cash | $19.00K | $-28.00K | $-330.00K | $4.00K | $399.00K | $231.00K | $1.81M | $-992.00K | $-1.05M | $-177.00K | $104.54M | $79.00K | $85.00K | $81.00K | $418.00K | $-169.00K | $27.00K | $83.00K |
| Net Change in Cash | $118.11M | $11.92M | $35.76M | $32.06M | $-9.14M | $-9.15M | $7.64M | $3.34M | $671.00K | $-14.99M | $-15.90M | $-36.66M | $51.57M | $27.42M | $7.80M | $-2.55M | $-3.74M | $-2.24M |
| Cash at End of Period | $223.14M | $105.03M | $93.11M | $57.35M | $25.29M | $34.44M | $43.59M | $35.94M | $32.60M | $31.93M | $46.92M | $62.82M | $99.48M | $47.91M | $20.49M | $12.69M | $15.24M | $18.98M |
| Cash at Beginning of Period | $105.03M | $93.11M | $57.35M | $25.29M | $34.44M | $43.59M | $35.94M | $32.60M | $31.93M | $46.92M | $62.82M | $99.48M | $47.91M | $20.49M | $12.69M | $15.24M | $18.98M | $21.22M |
| Operating Cash Flow | $-667.00K | $-1.82M | $-947.00K | $3.49M | $-7.96M | $-15.18M | $-8.45M | $-4.17M | $-13.97M | $-10.78M | $-7.88M | $-12.97M | $-8.48M | $-6.74M | $-5.62M | $-2.38M | $-3.77M | $-2.33M |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-667.00K | $-1.82M | $-947.00K | $3.49M | $-7.96M | $-15.18M | $-8.45M | $-4.17M | $-13.97M | $-10.78M | $-7.88M | $-12.97M | $-8.48M | $-6.74M | $-5.62M | $-2.38M | $-3.77M | $-2.33M |
Eliem Therapeutics Dividends
Explore Eliem Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Eliem Therapeutics News
Read the latest news about Eliem Therapeutics, including recent articles, headlines, and updates.
Climb Bio to Host Virtual Investor Event on October 15, 2024
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio's management team and an external expert who will provide an update to the investment community on the Company's strategy and focus on developing therapeutics for immune-mediated diseases.
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.
Eliem Therapeutics Reports Second Quarter Financial Results
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents of approximately $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for budoprutug SEATTLE and CAMBRIDGE, United Kingdom, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem” or the “Company”), today reported financial results for the quarter ended June 30, 2024 and provided a business update. “Following the close of the Tenet Medicines acquisition and the concurrent financing, we believe Eliem is well-positioned as we transition to becoming a leading development stage immunology company,” said Dr. Aoife Brennan, CEO of Eliem.
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia.
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of the Russell stock indexes, effective today.
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm
PHILADELPHIA , April 15, 2024 /PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders. The investigation seeks to determine whether Eliem issued false and misleading statements and/or failed to disclose material facts to investors in connection with recent corporate actions, thereby violating the securities laws and causing harm to the company's shareholders.
ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders. Halper Sadeh encourages Eliem shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Eliem and its board violated the.
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Companies to host webcast today, April 11, 2024 at 8:30 a.m. EDT SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”) and Tenet Medicines, Inc. (“Tenet”), a development-stage private biotechnology company, today announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet.
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. Eliem Therapeutics came to this decision after completing a review of the company and its various programs.
Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself
Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal excitability disorders, said it is exploring its strategic options. The Seattle and Cambridge, U.K.-based company said it has halted the development of its Kv7 program, which was focused on treatments for pain and epilepsy.
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in the process.
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem's president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET.
5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting
Eliem Therapeutics Inc's (NASDAQ: ELYM) ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) failed to achieve statistically significant separation from placebo on the trial's primary endpoint of daily pain score. The Company will longer pursue the.
Eliem Therapeutics to Present at Stifel's 2022 CNS Days
SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem's president and chief executive officer, will present at Stifel's 2022 CNS Days being held virtually on Tuesday, March 29, 2022 at 9:30 AM ET.
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem's president and chief executive officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 3:00 PM ET.
Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems, today announced the closing of its initial public offering of 7,360,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 960,000 additional shares of common stock, at a public offering price of $12.50 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Eliem, were $92.0 million. All of the shares in the offering were sold by Eliem.
Eliem Therapeutics Announces Pricing of Initial Public Offering
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced the pricing of its initial public offering of 6,400,000 shares of common stock at a public offering price of $12.50 per share. All of the shares are being offered by Eliem. Eliem has granted the underwriters a 30-day option to purchase up to an additional 960,000 shares of common stock at the initial public offering price. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Eliem, are expected to be $80.0 million, excluding any exercise of the underwriters' option to purchase additional shares of common stock.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ELYM.